CA2395742A1 - Compositions comprenant des acides nucleiques incorpores dans des particules minerales bilamellaires - Google Patents

Compositions comprenant des acides nucleiques incorpores dans des particules minerales bilamellaires Download PDF

Info

Publication number
CA2395742A1
CA2395742A1 CA002395742A CA2395742A CA2395742A1 CA 2395742 A1 CA2395742 A1 CA 2395742A1 CA 002395742 A CA002395742 A CA 002395742A CA 2395742 A CA2395742 A CA 2395742A CA 2395742 A1 CA2395742 A1 CA 2395742A1
Authority
CA
Canada
Prior art keywords
composition according
nucleic acid
exchangeable
mineral
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002395742A
Other languages
English (en)
French (fr)
Inventor
Bruno Pitard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9916707A external-priority patent/FR2803206A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2395742A1 publication Critical patent/CA2395742A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002395742A 1999-12-30 2000-12-27 Compositions comprenant des acides nucleiques incorpores dans des particules minerales bilamellaires Abandoned CA2395742A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9916707A FR2803206A1 (fr) 1999-12-30 1999-12-30 Composition comprenant des acides nucleiques, preparation et utilisation
FR99/16707 1999-12-30
US18567900P 2000-02-28 2000-02-28
US60/185,679 2000-02-28
PCT/FR2000/003702 WO2001049869A1 (fr) 1999-12-30 2000-12-27 Compositions comprenant des acides nucleiques incorpores dans des particules minerales bilamellaires

Publications (1)

Publication Number Publication Date
CA2395742A1 true CA2395742A1 (fr) 2001-07-12

Family

ID=26235199

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002395742A Abandoned CA2395742A1 (fr) 1999-12-30 2000-12-27 Compositions comprenant des acides nucleiques incorpores dans des particules minerales bilamellaires

Country Status (7)

Country Link
EP (1) EP1246931A1 (es)
JP (1) JP2003519241A (es)
AU (1) AU2860401A (es)
CA (1) CA2395742A1 (es)
IL (1) IL150476A0 (es)
MX (1) MXPA02006528A (es)
WO (1) WO2001049869A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826279A1 (fr) * 2001-06-26 2002-12-27 Aventis Pasteur Composition vaccinale comprenant un compose de type hydrotalcite
DE10237518A1 (de) * 2002-08-16 2004-02-26 Süd-Chemie AG Verwendung von Schichtdoppelhydroxiden zur An- bzw. Abreicherung von Biomolekülen aus flüssigen oder fluiden Medien
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
DE102005060392A1 (de) 2005-12-16 2007-06-21 Süd-Chemie AG Verfahren zur Abtrennung von Proteinen aus flüssigen Medien
US8507200B2 (en) 2007-02-09 2013-08-13 Northwestern University Particles for detecting intracellular targets
CA2682135A1 (en) * 2007-04-17 2008-10-30 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
AU2008259907B2 (en) 2007-05-30 2014-12-04 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2010060110A1 (en) 2008-11-24 2010-05-27 Northwestern University Polyvalent rna-nanoparticle compositions
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CN102666879B (zh) 2009-10-30 2016-02-24 西北大学 模板化的纳米缀合物
WO2013040499A1 (en) 2011-09-14 2013-03-21 Northwestern University Nanoconjugates able to cross the blood-brain barrier
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3220895B1 (en) 2014-11-21 2022-08-31 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
AU1194697A (en) * 1995-12-21 1997-07-17 Quest International B.V. Particle compositions
KR100359716B1 (ko) * 1998-09-11 2003-04-21 (주)나노하이브리드 유전자의보관및전달이가능한생-무기하이브리드복합체및그의제조방법

Also Published As

Publication number Publication date
WO2001049869A1 (fr) 2001-07-12
AU2860401A (en) 2001-07-16
MXPA02006528A (es) 2002-11-29
EP1246931A1 (fr) 2002-10-09
JP2003519241A (ja) 2003-06-17
IL150476A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
CA2395742A1 (fr) Compositions comprenant des acides nucleiques incorpores dans des particules minerales bilamellaires
Lee et al. Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing
RU2651498C2 (ru) Молекулы искусственной нуклеиновой кислоты
EP0770140B1 (fr) Composition contenant des acides nucleiques et des polymeres cationiques, preparation et utilisation
EP0738328B1 (fr) Composition contenant des acides nucleiques, preparation et utilisations
EP0743984A1 (fr) Composition contenant des acides nucleiques, preparation et utilisations
JP5697123B2 (ja) 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法
EP1268609B1 (fr) Procede de preparation de polyalkylenimines fonctionnalises, compositions les contenant et leur utilisations
Ohmori et al. Importance of hydrophobic region in amphiphilic structures of α-helical peptides for their gene transfer-ability into cells
WO2019220058A1 (fr) Substitution de la coiffe des arn messagers par deux séquences d'arn introduites à leur extrémité 5'
Du et al. CRISPR/Cas9 systems: Delivery technologies and biomedical applications
JP2012509904A (ja) 核酸送達組成物および核酸送達法
FR2803206A1 (fr) Composition comprenant des acides nucleiques, preparation et utilisation
US20220290157A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis
FR2724935A1 (fr) Compositions nanoparticulaires contenant des derives nucleotidiques, leur preparation et leur emploi en therapeutique
EP1066396A1 (fr) Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
FR2805271A1 (fr) Procede de preparation de polyalkylenimines fonctionnalises, compositions les contenant et leurs utilisations
Kutwin et al. Influence of GO-Antisense miRNA-21 on the Expression of Selected Cytokines at Glioblastoma Cell Lines
CN117821468A (zh) 肺靶向可溶性PD-L1 mRNA脂质纳米颗粒及其应用
KR20230120590A (ko) 유전자 전달용 올리고뉴클레오티드 및 이를 포함하는 유전자 전달용 지질나노입자
FR2776669A1 (fr) Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
KR20240072931A (ko) 히스티딘을 포함하는 지질 나노입자 및 그 제조방법
JP2023506293A (ja) ポリプロピレンイミンを含む非ウイルスベクター
CA2353576A1 (fr) Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations
FR2822156A1 (fr) Oligonucleotides pour la regulation du gene codant pour le tnf alpha et/ou de genes sous son controle et leurs applications

Legal Events

Date Code Title Description
FZDE Discontinued